Metabolic Actions Could Confound Advantageous Effects of Combined Angiotensin II Receptor and Neprilysin Inhibition
Hypertension - United States
doi 10.1161/hypertensionaha.110.165159
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 1, 2011
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)